With Gilead Sciences Inc. barely a month away from a possible history-making FDA approval of an all-oral regimen for hepatitis C virus (HCV), the American Association for the Study of Liver Diseases (AASLD) meeting in Washington put the spotlight on other HCV contenders over the weekend, with much of the buzz focused on a protease inhibitor/NS5A inhibitor combination from Merck & Co. Inc.